Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined non-luminal subtypes of HR+/HER2- mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post-endocrine treatment decisions.
Authors
- O. Castillo
- Silvia Vázquez (ORCID: https://orcid.org/0000-0003-0155-901X)
- Guillermo Villacampa (ORCID: https://orcid.org/0000-0003-4868-6585)
- N. Chic
- Cristina Hernándo (ORCID: https://orcid.org/0000-0002-6865-4196)
- Manuel Alva
- Lorea Villanueva (ORCID: https://orcid.org/0000-0003-1858-7076)
- Paula Blasco
- Sara Cano-Crespo (ORCID: https://orcid.org/0000-0003-2224-3276)
- Fernando Salvador (ORCID: https://orcid.org/0000-0002-5442-1754)
- Mafalda Oliveira
- E Seguí
- A. Prat
- Salvador Blanch (ORCID: https://orcid.org/0009-0008-9553-2179)
- Juan Antonio Virizuela
- Adela Rodríguez Hernandez
- B. Conte
- Ana Vivancos
- Esther Sanfeliu
- Eva Ciruelos
- Fara Brasó-Maristany
- Patricia Galván
- Juan Manuel. Ferrero-Cafiero
- Tomás Pascual
Institutions
- Hebron University (PS)
- Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
- Institut d'Investigació Biomédica de Bellvitge (ES)
- Hospital Universitario Virgen Macarena (ES)
- Hospital Clínico Universitario de Valencia (ES)
- Departament de Salut (ES)
- Hospital Universitario 12 De Octubre (ES)
- MedSIR (Spain) (ES)
- Vall d'Hebron Institut de Recerca (ES)
- Fundación Instituto Valenciano de Oncología (ES)
- Institut Català d'Oncologia (ES)
- Hospital Clínic de Barcelona (ES)
- Cancer Clinic (US)
- Vall d'Hebron Hospital Universitari (ES)
- Solti (ES)
- Oryzon Genomics (Spain) (ES)
- INCLIVA Health Research Institute (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1158/1078-0432.ccr-25-2570
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00